Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL106838 | 0.72 | L3MBTL1 (0.47) | HPGDKDM4EGLAL3MBTL1RAB9A | |
| SCHEMBL109276 | 0.68 | KCNA5 (0.35) | KDM4EALDH1A1CYP26A1MEN1KMT2A | |
| SCHEMBL29283265 | 0.68 | GABRA5 (0.46) | HPGDKDM4ERAB9ASMN1; SMN2NPC1 | |
| SCHEMBL103684 | 0.68 | CYP26A1 (0.34) | CYP26A1 | |
| SCHEMBL1141772 | 0.67 | STK17B (0.40) | MEN1KMT2A | |
| SCHEMBL25030252 | 0.67 | GABRA5 (0.45) | HPGDRAB9ASMN1; SMN2NPC1POLB | |
| SCHEMBL15717952 | 0.67 | CA12 (0.58) | HTT | |
| SCHEMBL1141433 | 0.66 | AAK1 (0.41) | L3MBTL1CYP26A1 | |
| SCHEMBL30692794 | 0.66 | NPC1 (0.40) | RAB9ANPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL508699 | 0.66 | CYP26A1 (0.31) | CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183254-B1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2017-06-21 | — | — | EP | disclosed |
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2014-06-26 | — | — | US | disclosed |
| US-8759522-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-06-24 | — | — | US | disclosed |
| US-8729268-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-05-20 | — | — | US | disclosed |
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | Mirati Therapeutics, Inc. | 2012-04-19 | — | — | US | disclosed |
| EP-2426108-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MethylGene Inc. (CA) | 2012-03-07 | — | — | EP | disclosed |
| EP-2332536-A1 | Inhibitors of protein tyrosine kinase activity | MethylGene Inc. (CA) | 2011-06-15 | — | — | EP | disclosed |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| EP-2183254-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | MethylGene Inc. (CA) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009026717-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | MAP3K19, MAP3K9, MAP4K2 | HPGD 1051/4885KDM4E 776/4885GLA 4112/4885 |
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | PTK2B, PRKACA, DSTYK | HPGD 2714/4885KDM4E 1640/4885GLA 1617/4885 |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | ABL1, ERBB2, TYRO3 | HPGD 3391/4885KDM4E 1254/4885GLA 3054/4885 |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | ABL1, ERBB2, TYRO3 | HPGD 3391/4885KDM4E 1254/4885GLA 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.